AKTUELLE ASPEKTE DER IMMUNSUPPRESSIVEN THERAPIE NACH INTRATHORAKALEM ORGANERSATZ

Translated title of the contribution: Modern aspects in immunosuppressive therapy after intrathoracic organ replacement

Matthias Loebe, M. Hummel, M. Musci, R. Sodian, O. Grauhan, R. Hetzer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

As intrathoracic organ transplantation has evolved as a routine procedure for treating endstage heart or lung disease with good early results, interest focusses nowadays on consequences of long-term immunosuppression. These are primarily impaired renal function, induction of malignancies, and chronic rejection. We are presenting our experience in 902 intrathoracic organ transplant recipients. Over the years, we have changed our immunosuppression from rather standardized to individualized treatment based on immunologic monitoring and non-invasive day-by-day rejection monitoring. Early postoperative infectious complications diminished after reducing induction therapy with ATG in compromized recipients (for example diabetics, post mechanical assist, elderly recipients). Thus use of Urodilatin helped preventing severe renal failure and allowed high levels of Cyclosporin A in the early phase after transplantation. We hope that this individualized immunosuppressive therapy will further lead to improved long-term graft survival and reduced incidence of graft vasculopathy and reduced induction of malignancies.

Original languageGerman
Pages (from-to)200-204
Number of pages5
JournalTransplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft
Volume7
Issue number4
StatePublished - 1995
Externally publishedYes

Fingerprint

Immunosuppressive Agents
Immunosuppression
Transplants
Immunologic Monitoring
Organ Transplantation
Graft Survival
Cyclosporine
Lung Diseases
Renal Insufficiency
Heart Diseases
Neoplasms
Therapeutics
Transplantation
Kidney
Incidence

Keywords

  • heart transplantation
  • heart-lung transplantation
  • immunologic monitoring
  • immunosuppression
  • malignancy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Cite this

AKTUELLE ASPEKTE DER IMMUNSUPPRESSIVEN THERAPIE NACH INTRATHORAKALEM ORGANERSATZ. / Loebe, Matthias; Hummel, M.; Musci, M.; Sodian, R.; Grauhan, O.; Hetzer, R.

In: Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft, Vol. 7, No. 4, 1995, p. 200-204.

Research output: Contribution to journalArticle

@article{1743ff7bbc4141ea9abc9ade03f36a56,
title = "AKTUELLE ASPEKTE DER IMMUNSUPPRESSIVEN THERAPIE NACH INTRATHORAKALEM ORGANERSATZ",
abstract = "As intrathoracic organ transplantation has evolved as a routine procedure for treating endstage heart or lung disease with good early results, interest focusses nowadays on consequences of long-term immunosuppression. These are primarily impaired renal function, induction of malignancies, and chronic rejection. We are presenting our experience in 902 intrathoracic organ transplant recipients. Over the years, we have changed our immunosuppression from rather standardized to individualized treatment based on immunologic monitoring and non-invasive day-by-day rejection monitoring. Early postoperative infectious complications diminished after reducing induction therapy with ATG in compromized recipients (for example diabetics, post mechanical assist, elderly recipients). Thus use of Urodilatin helped preventing severe renal failure and allowed high levels of Cyclosporin A in the early phase after transplantation. We hope that this individualized immunosuppressive therapy will further lead to improved long-term graft survival and reduced incidence of graft vasculopathy and reduced induction of malignancies.",
keywords = "heart transplantation, heart-lung transplantation, immunologic monitoring, immunosuppression, malignancy",
author = "Matthias Loebe and M. Hummel and M. Musci and R. Sodian and O. Grauhan and R. Hetzer",
year = "1995",
language = "German",
volume = "7",
pages = "200--204",
journal = "Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft",
issn = "0946-9648",
publisher = "Pabst Science Publishers",
number = "4",

}

TY - JOUR

T1 - AKTUELLE ASPEKTE DER IMMUNSUPPRESSIVEN THERAPIE NACH INTRATHORAKALEM ORGANERSATZ

AU - Loebe, Matthias

AU - Hummel, M.

AU - Musci, M.

AU - Sodian, R.

AU - Grauhan, O.

AU - Hetzer, R.

PY - 1995

Y1 - 1995

N2 - As intrathoracic organ transplantation has evolved as a routine procedure for treating endstage heart or lung disease with good early results, interest focusses nowadays on consequences of long-term immunosuppression. These are primarily impaired renal function, induction of malignancies, and chronic rejection. We are presenting our experience in 902 intrathoracic organ transplant recipients. Over the years, we have changed our immunosuppression from rather standardized to individualized treatment based on immunologic monitoring and non-invasive day-by-day rejection monitoring. Early postoperative infectious complications diminished after reducing induction therapy with ATG in compromized recipients (for example diabetics, post mechanical assist, elderly recipients). Thus use of Urodilatin helped preventing severe renal failure and allowed high levels of Cyclosporin A in the early phase after transplantation. We hope that this individualized immunosuppressive therapy will further lead to improved long-term graft survival and reduced incidence of graft vasculopathy and reduced induction of malignancies.

AB - As intrathoracic organ transplantation has evolved as a routine procedure for treating endstage heart or lung disease with good early results, interest focusses nowadays on consequences of long-term immunosuppression. These are primarily impaired renal function, induction of malignancies, and chronic rejection. We are presenting our experience in 902 intrathoracic organ transplant recipients. Over the years, we have changed our immunosuppression from rather standardized to individualized treatment based on immunologic monitoring and non-invasive day-by-day rejection monitoring. Early postoperative infectious complications diminished after reducing induction therapy with ATG in compromized recipients (for example diabetics, post mechanical assist, elderly recipients). Thus use of Urodilatin helped preventing severe renal failure and allowed high levels of Cyclosporin A in the early phase after transplantation. We hope that this individualized immunosuppressive therapy will further lead to improved long-term graft survival and reduced incidence of graft vasculopathy and reduced induction of malignancies.

KW - heart transplantation

KW - heart-lung transplantation

KW - immunologic monitoring

KW - immunosuppression

KW - malignancy

UR - http://www.scopus.com/inward/record.url?scp=0029620537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029620537&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 200

EP - 204

JO - Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft

JF - Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft

SN - 0946-9648

IS - 4

ER -